Purpose: Evaluate use of fixed and all-available look-backs to identify eligibility criteria and confounders among Medicare beneficiaries.
world populations. [1] [2] [3] To ensure comparable accuracy of information across comparator groups, longitudinal studies are routinely restricted to those who are continuously observed within the database for some uniform time period before exposure. 4 Potentially informative data occurring before this time period are discarded. 5 These fixed (or uniform) look-back periods are frequently used to define study eligibility criteria (eg, no observed history of exposures or outcomes and no recent cardiovascular events) and also to capture baseline covariates used to adjust for confounding.
Selecting a fixed look-back period requires investigators to weigh competing priorities. A longer period allows for a more thorough characterization of database enrollees but also selects narrower, smaller cohorts. In many cases, at least in the United States, database enrollment depends on a range of complex variables (eg, employment, socioeconomic status, marital status/family structure, health status, and age). It is unclear whether enrollment restrictions, which inadvertently condition on these characteristics, might impact findings.
Despite widespread use of methods that clearly favor the principal of comparative information-accuracy in epidemiology, methodologists have debated its importance relative to other threats to validity, such as covariate misclassification or selection bias, which may be reduced by using all of the available data. [6] [7] [8] [9] [10] Observing all historical (preexposure) information available in a database while requiring only minimal baseline continuous enrollment has been proposed as a possible compromise, which might improve capture of relevant medical history and selection of more inclusive, representative cohorts. 6, 7 The common argument against using all-available look-backs is that for many research questions, we might expect the completeness and longitudinal breadth of available data to vary informatively between exposure (eg, when comparing users to nonusers) or outcome groups, threatening validity of estimates.
To date, there has been limited research exploring the use of allavailable data to characterize patient medical histories, primarily using simulations of simplified scenarios. 7, 10 Research does exist demonstrating that effect estimates may vary depending on the length of fixed look-backs used to exclude (or washout) patients with prior exposures. 11, 12 Only one paper has been published exploring use of all-available look-backs in actual data with multiple interrelated covariates but it does not address the issue of cohort selection. 13 Thus, we sought to evaluate the application of multiple look-back approaches to select patients and classify covariates in an observational cohort study set in the Medicare claims database. In this study, we estimate the effects of statin initiation (compared with non-initiation) after an outpatient office visit on (1) a null outcome (6-month cancer incidence) and (2) a protective outcome (2-year all-cause mortality).
2 | METHODS
| Ethics statement
This study was reviewed and approved by University of North Carolina's institutional review board (study: 16-1066), which waived requirements for informed consent and HIPAA authorization. Data access was governed by a data use agreement with the Centers for Medicare and Medicaid Services (CMS).
| Study population
We used a 20% random sample of Medicare fee-for-service benefi- indicative of strong contraindications for statin therapy. These eligibility criteria were meant to imitate those of the Heart Protection Study. 14 We identified 3 cohorts by applying different look-back periods to the set of potential index visits identified by using the 6-month period above. For the all-available database history approach, we required no additional continuous enrollment, but excluded all visits preceded by any observable statin claims or cancer (other than nonmelanoma skin cancer) diagnosis/treatment. When applying the conventional 1-year or 3-year fixed look-back periods, we further restricted the cohort to those continuously enrolled throughout the entire look-back and then excluded visits with prevalent statin use or cancer history within these look-back periods. When beneficiaries had multiple eligible outpatient visits, we selected the first eligible visit within each exposure group (ie, the first eligible initiation visit and the first eligible non-initiation visit).
A study schematic illustrating the overall study design is presented in Figure 1 .
KEY POINTS
• Using a 3-year fixed or all-available look-back appears favorable to the widely used 1-year fixed look-back, especially when exclusion of prior outcomes is necessary.
• The 3-year fixed look-back produced the least biased point estimate, closely followed by the all-available approach.
• The continuous enrollment required for the 3-year fixed look-back decreased the sample size substantially (excluding 62% initiators and 59% of initiators), reducing the precision of estimates.
• The look-back approaches did not differ in their ability to control for confounding.
• Cohorts selected by using all-available look-backs were broader and clearly defined than those selected by using short fixed look-backs.
| Exposure
We classified each index outpatient visit as either a statin initiation or non-initiation by evaluating whether there was a claim for a statin dispensing at a pharmacy in the subsequent 14 days.
| Outcomes and follow-up
In separate analyses, we evaluated the effect of statin initiation on 2 outcomes (1) incident cancer within 6 months and (2) all-cause mortality within 2 years. For both, follow-up began on the day after the 14-day exposure assessment window (15 days after the index outpatient visit). Individuals with either outcome during this 14-day window (≈0.4% of visits) were excluded. For both outcomes, we censored follow-up when individuals disenrolled from the study database or the end of available data, December 31, 2012. For the short-term cancer outcome, we also censored follow-up when patients died or switched exposures. Exposure switching was defined as a statin fill for non-initiators and 14 days without medication coverage for initiators.
| Covariates
We used the index visit claim to assess information on patient demographics (age, sex, race, geographic region, and calendar year). Then, using the various look-back approaches, we assessed historical claims to classify baseline health behaviors, diagnoses, and procedures by 
| Statistical analyses
Within each cohort, we evaluated covariate imbalance between initiators and non-initiators by using the average standardized mean difference 15 and then used multivariable logistic regression to estimate a propensity score (ie, baseline probability of statin initiation conditional on baseline covariates) 16 corresponding to each index visit in the cohort. Propensity score models included all variables that were identified as risk factors for the outcome using any look-back approach. A more detailed description of the approach to variable selection for the propensity score model is available in eAppendix S1, and the sets of selected variables for each outcome are given in the footnote of Table 1 .
In each analysis, we estimated crude and adjusted hazard ratios (HR) for the effect of interest by using Cox proportional hazard models. We used the robust variance to estimate confidence intervals to account for beneficiaries who entered the cohort twice (for an initiation and non-initiation). 17 We adjusted estimates to account for differences in measured baseline covariates by using standardized mortality ratio weighting (SMRW) with and without 1% asymmetric trimming of the propensity score. [18] [19] [20] In a subanalysis of the cancer outcome, we accounted for competing risk of mortality by fitting the Fine and Grey subdistribution hazard model. 21, 22 We used the cumulative hazard function to plot cumulative incidence curve estimates of the risk difference (ie, the difference in cumulative incidence at each point in time) over the course of follow-up.
For the 6-month cancer analysis, we anticipated a null effect, since it is implausible for any statin exposure to have a causal effect on the incidence of clinically detectable cancer within such a short interval after initiation. 23 While this effect should be null, we expected estimates to be biased by uncontrolled differences in selection, baseline cancer risk, and cancer surveillance during follow-up. Thus, we estimated mean squared error (MSE) using the equation: MSE = (1 − log-HR) 2 + (Standard Error log-HR ) 2 . For the analysis evaluating the effect of statins on mortality, the results of 2 meta-analyses served as alloyed gold standards.
24,25

| Subanalyses
Unlike the primary analysis, which applied the same look-back uniformly for all study components (eg, exclusion of prevalent statin users and assessing confounders for adjustment), we conducted a subanalysis varying each component individually and holding the others fixed. This allowed us a more granular exploration of the mechanisms through which look-backs might alter findings. We also conducted a subanalysis with an active comparator, ie, high-potency statins vs low-potency statins.
All analyses were conducted in SAS 9.4 (SAS Institute, Cary, NC, USA), and figures were produced by using SAS 9.4 or R 3.3.1 (R Foundation for Statistical Computing; Vienna, Austria).
| RESULTS
The all-available cohort (71 347 initiators, 476 832 non-initiators) was slightly smaller than the 1-year fixed cohort (86 923 initiators, 559 471 non-initiators) and much larger than the 3-year fixed cohort (18 918 initiators, 204 249 non-initiators) ( Table 1) . As implemented here, the all-available look-back had a far less restrictive continuous enrollment requirement compared with the 1-year look-back. However, the all-available cohort was smaller than 1 year because it a For each person, we kept only the first eligible outpatient visit within each exposure group (i.e. the first eligible initiation visit and the first eligible non-initiation visit). b We excluded any patients who had the cancer outcome or died in the 14-day exposure assessment period. Variables included in propensity score (PS) models for both the 6-month cancer analysis and the 2-year mortality analysis: sex, age (as a continuous linear term, continuous squared term, and categorical term with 5-year categories), calendar year, race, inpatient stays/month (continuous linear term and categorical term divided by quintile), outpatient visits/month, skilled nursing facility admissions/month, unique drugs/month, smoking, substance abuse, anemia, chronic obstructive pulmonary disease, dementia, hyperlipidemia, venous thromboembolism, cancer screening, cardiac stress test, colonoscopy, hs-CRP, sulfonylurea, insulin, and home oxygen.
Variables only included in PS models for the 6-month cancer analysis: inclusion for diabetes (≤6 months), diabetes (>6 months), stroke (>6 months), chronic liver disease (>6 months), arthritis, rheumatoid arthritis, gastrointestinal bleed, PSA testing, and creatinine. Variables only included in PS models for the 2-year mortality analysis: inclusion for stroke (≤6 months), chronic kidney disease (>6 months), obesity, angiography, pulmonary circulation disorders, peripheral vascular disease, osteoarthritis, asthma, atrial fibrillation, psychiatric disorder, inflammatory bowel, paralysis, sepsis, vertigo, lipid panel, echocardiograph, fecal occult blood testing, ARB, diuretics, thiazide, ambulatory life support, weakness, and wheelchair.
b
These counts denote unique observations in the dataset. Patients who enter the cohort twice for eligible initiations and non-initiations are counted twice in the N total statistic (one for each exposure). Since they cannot appear twice in the same exposure group, the N statin statistic denotes counts of unique patients.
excluded more patients with identifiable history of statin use and/or cancer ( Figure 2) . With respect to the proportions of patients excluded for having prior statin use and cancer history, the all-available approach was less restrictive than the 3-year approach, but much more restrictive than the 1-year approach ( Figure S1 ). Among non-initiators, cancer incidence during follow-up was elevated in cohorts selected by using shorter fixed look-backs (1 year: 2.0% vs 3 years: 1.5%). Cancer incidence in the all-available cohort most closely resembled that of the 3-year fixed cohort. For all look-backs, the inclusion criteria for recently elevated cardiovascular risk were most frequently met by the presence of either diabetes or stroke.
In the all-available cohort, non-initiators had less available Part It is important to note that most beneficiaries who entered the study twice entered the study as a non-initiator prior to entering as an initiator. The proportion of initiators who had a dual entry in the cohort as a non-initiator did not vary widely by look-back approach, ranging from 70% of initiators for the 3-year approach to 75% for the 1 year (Table S1 ).
Compared with non-initiators, initiators were younger, used more preventive health services/screening, and were more likely to be diabetic (Table S2 ). Broadly speaking, the all-available approach tended to identify greater imbalance in measured covariates compared with fixed look-back approaches, although in most cases not by much (Figure 4 ).
For all look-back approaches, covariates were well balanced (standardized difference < 5%) after SMRW. Propensity score distributions under each look-back approach are presented in Figures S3 and S4 .
In analyses of the 6-month cancer outcome, SMRW-adjusted estimates of the HRs generated by using fixed look-backs ranged from Table S5 .
FIGURE 2
Bar chart showing the proportion excluded for each of 3 eligibility criteria applied by using different look-back approaches and the final proportion eligible for inclusion a When using the fixed look-back approaches, actual classification is constant over time. The upward slope of the curves shown in this figure reflect the diminished power of using all-available database history in earlier calendar years, when available historical data in the database is sparse.
FIGURE 3 Proportion of the final cohort with observable history in the database of (A) statin use and (B) cancer for the 1-year and 3-year look-back approaches
In the subanalysis independently varying the look-back to define different study components, estimates were generally insensitive to look-back choice (Table 1 ). An important exception is that in the 6-month cancer analysis, estimates dramatically (and significantly) improved when we excluded patients with prior cancer history using In Figure 5 , we present cumulative estimates of the risk difference over the course of the 6-month follow-up for each look-back approach. (The corresponding cumulative incidence curves are available in Figures S5 and S6 .) Risk differences estimated by using allavailable and 3-year fixed look-backs were generally closer to the presumed truth (null) than the estimates produced by using 1-year fixed look-backs. Throughout most of follow-up, the adjusted 3-year lookback estimate is the closest to the true null though, by the end of follow-up, the magnitude of the bias in the all-available estimate was comparable. The results of the short-term cancer analysis accounting for the competing risk of mortality were identical to the primary analysis (data not shown). Figure 6 presents the cumulative risk difference estimates for the 2-year mortality analysis. Throughout follow-up, estimates produced by the different look-back approaches overlapped one another nearly perfectly.
| DISCUSSION
For the effects explored in these analyses, differences in estimates produced using all-available and 3-year fixed look-backs were small, with substantial overlap in confidence intervals (Table 1) . Point estimates produced by the 3-year look-back were slightly less biased than the all-available approach, but less precise. In claims studies, bias is typically of greater concern than precision. However, it is still necessary to understand trade-offs in bias and precision, since their relative importance will depend on the specific study question and population.
Generally speaking, the all-available approach tracked closely with the 3-year look-back in subanalyses where we independently varied specific look-back components (holding the others fixed).
Two meta-analyses evaluating the effect of statin use (vs nonuse)
on 5-year mortality among elderly patients with established cardiovascular risk estimated risk ratios of 0.85 (95% CI: 0.78, 0.93) 25 and 0.78 (95% CI: 0.65, 0.89). 24 After SMRW-adjustment and trimming, all lookback approaches produced point estimates for 2-year mortality HR that fell in the plausible range between the point estimates for the risk ratios estimated by these meta-analyses. Two randomized doubleblinded trials evaluating effects over shorter follow-up (2 26 and 3 27 years) produced estimates of 0.76 (95% CI: 0.51, 1.00) and 0.75 a We smoothed the curves using penalized B-splines with 15 knots.
FIGURE 5
Crude and standardized mortality ratio weighting (SMRW)-adjusted cumulative risk differences in the 6-month cancer analysis using the all-available, 3-year, and 1-year look-back approaches a Positive standardized differences indicate greater mean or proportion observed among initiators b Dashed grey lines mark standardized differences of -0.05 and 0.05 c This figure presents all variables which 1) were included in the propensity score model for the 6-month cancer analysis, 2) had a crude standardized difference > 0.05 for any look-back approach, and 3) was prevalent in at least 5% of users or non-users, for any look-back approach.
FIGURE 4
Average standardized mean difference for selected variables in the analysis of 6-month cancer, for the crude (white) analysis and standardized mortality ratio weighting (SMRW) analysis before (black) and after (grey) 1% asymmetric trimming (95% CI: 0.49, 0.99), respectively. Trial estimates may provide a reasonable benchmark. However, we cannot use them to assess the bias of the estimates produced in our study since we are evaluating statin effectiveness, not efficacy, in a broader, more heterogeneous population than was evaluated in the trials. Furthermore, given that treatment adherence is likely worse in an observational setting, the plausible range for estimates in our study may be closer to the null than the estimates produced by the trials.
In the analyses we present, there were 4 key aspects of the cohort that were affected by the look-back period (Table 1 presents results of individually varying each component): the continuous enrollment requirement, exclusion of prevalent statin users, exclusion of patients with a history of the cancer outcome, and assessment of confounders. We discuss the way in which the look-back approaches affected each of these in turn.
| Imposing continuous enrollment requirements
We compared statin initiators and non-initiators because it seemed especially plausible that these exposure groups would exhibit striking differences in the accuracy/availability of database information (eg,, as a function of health services utilization and available database history). Indeed, due to our design, we observed less database history among non-initiators, with the median Part A/B look-back being about 8 months shorter among non-initiators. We did not observe meaningful variation in available database history with respect to either the cancer or the mortality outcome. In subanalyses, independently varying the continuous enrollment requirement had little impact on crude or adjusted effect estimates (Table 1) .
| Excluding prevalent statin users
Proper exclusion of prevalent statin use is necessary to correctly align time at risk after true initiation. A substantial proportion of cohorts selected by using short fixed look-backs had identifiable prior statin use when all-available data were considered. Unrecognized prior statin exposure appeared nondifferential when using a longer fixed look-back but was more common among initiators when using a short fixed look-back. This may indicate that short fixed lookbacks are prone to including prevalent users (eg, patients paying outof-pocket, recent/short-term discontinuers). Presumably, these patients were identified and excluded by the longer 3-year look-back.
Independently varying the look-back for excluding prevalent statin users produced changes in estimate in the 2-year mortality analysis but not the 6-month cancer analysis (since the true effect in the cancer analysis is null) ( Table 1 ).
| Excluding prevalent cancer cases
Considering all-available data, the short 1-year look-back cohort incorrectly included 18% and 23% of initiators and non-initiators within the fixed look-back period may reduce the number of unrecognized cancers in the cohort that can be reclassified using data outside the look-back period. Failing to properly exclude patients with observable cancer history in the database is more likely to bias estimates of the effect of statins on short-term cancers, where the truth is known to be null. We observed this in the subanalysis independently varying exclusion for patients with a history of the cancer outcome, producing meaningful improvements in estimates when using longer look-backs (eg, 3-year or all-available approaches) to exclude these patients (Table 1) . This is the most plausible explanation for why the all-available and 3-year fixed analyses of the short-term cancer outcome produced less biased estimates than the 1-year fixed look-back.
| Assessment and control for confounding
To informally evaluate the impact of different look-backs on identifying and adjusting for confounding, we can observe change in crude estimates after SMRW adjustment. Unfortunately, in the evaluation of the short-term cancer outcome, the only analysis where we can reasonably estimate bias and MSE, SMRW adjustment had a nearly a We smoothed the curves using penalized B-splines with 15 knots.
FIGURE 6
Crude and standardized mortality ratio weighting (SMRW)-adjusted cumulative risk differences in the 2-year mortality analysis using the all-available, 3-year, and 1-year look-back approaches negligible impact on estimates (Table 1) This study has some important limitations. Since this paper explores an applied example in real-world data, it is difficult to know the truth or evaluate true bias as earlier simulation work has. Single empirical examples have, however, previously been successfully used to compare different study designs. 28 A unique limitation for cancer analysis, where the true effect is null, is that imprecise approaches (eg, a 3-year fixed look-back) will be more likely to produce correct inference (ie, confidence intervals containing the null). Also, it is likely that analyses of the short-term cancer outcome remains confounded by variables that we could not measure in the Medicare data. Minimal change in the cancer estimates before and after adjustment indicates a limited ability to control for confounding when using claims data. However, in analyses of the mortality outcome, where SMRW adjustment resulted in substantial changes in estimates, all look-backs produced similar estimates.
Furthermore, we selected a population with recently observed elevated cardiovascular risk to assure that everyone would have a plausible indication for statin therapy. However, it is possible that our estimates remain confounded factors that we measure within the claims data, which may lead a physician to withhold statins from an otherwise indicated patient (eg, frailty). Our design allowed the same patient to enter as both a statin initiator and non-initiator, and the great majority who did entered first as a non-initiator, ie, with less available look-back. It is unlikely that this impacted the relative performance of the different look-backs since the frequency of repeated patients in the cohort did not vary widely by look-back approach. Furthermore, we adjusted estimates using SMRW (which weights to the treated population), preventing us from double-counting patients who were eligible to enter the cohort in both exposure groups, since they can only appear once as an initiator. Finally, determinants of continuous enrollment, and thus performance of different look-back methods, may vary across different study questions, populations, and databases, which may limit the generalizability of our findings.
Further research exploring these approaches is needed. Formal quantitative bias analysis may be a promising method to explore (and/or bound) the impact that differential database history might have on the performance of different look-backs. 29 Our decision to select each beneficiary's first eligible visit may reduce the benefit of using all-available database information and potentially increases differential information accuracy by exposure status. Our motivation for using this approach was to provide a conservative evaluation of all-available look-backs in a potentially problematic setting.
However, further research is needed exploring the performance of different look-back approaches when using alternative cohort selection strategies (eg, randomly sampling across person-time).
Our study design and choice of comparators prevented us from doing so here.
Within this applied setting, we contribute evidence that the allavailable look-back is a tenable alternative to using long 3-year lookbacks, which produced the least biased point estimate, to characterize patients in longitudinal database studies. Both approaches outperformed the widely used 1-year fixed look-back. This indicates that in frequently encountered settings where 3-year fixed look-backs are not feasible (eg, because of the statistical power required to estimate effects or the structure of the database), the all-available look-back may be the preferred method. The case for all-available look-backs is made stronger by the fact that the comparability of information accuracy in study groups being compared can be empirically evaluated (eg, the amount of available baseline data or the frequency of healthcare interactions), at least to some degree. The look-backs did not appear to vary substantially with respect to their ability to control for confounding. However, selecting a study population by using all-available look-backs produced a cohort with less prevalent exposure and cancer reducing bias in analyses where exclusion of patients with prior cancers was essential. By not requiring long periods of continuous enrollment, cohorts selected by using the allavailable approach were broader and more clearly defined than cohorts selected by using fixed look-backs, enhancing the precision of estimates.
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